Drug Trial Radar · NCT07540442
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Apr 17, 2026
Primary completion
Jan 5, 2027
Study completion Nov 9, 2027
Sponsor
- Lead sponsor
- Shanghai Mabgeek Biotech.Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
Conditions
- Dermatitis, Atopic
Interventions
MG-K10 Injection (Humanized Monoclonal Antibody)Drug
loading dose (SC) at Week 0, followed by a single dose Q2W through Week 52
Placebo for MG-K10Drug
Initial loading dose (SC), then single dose Q2W through Week 52
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving EASI-75 ( ≥75% reduction from baseline )Time frame: week 16
- Proportion of participants achieving IGA score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baselineTime frame: week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital Of China Medical University
Shenyang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.